Effect of second-generation antipsychotics on employment and productivity in individuals with schizophrenia: an economic perspective

PharmacoEconomics
Mauro PercudaniMichele Tansella

Abstract

Schizophrenia is a serious mental illness that imposes a considerable burden not only on those who are ill, but also on their families, neighbours and the wider society. Costs associated with treating people with schizophrenia are those derived from the use of a wide range of services provided by public psychiatric facilities and/or by voluntary and private agencies. In addition, a large part of the economic impact of schizophrenia is related to the difficulties that patients encounter in finding and keeping paid employment. The introduction of second-generation antipsychotics (SGAs), also defined as atypicals, has increased the therapeutic options available for individuals with schizophrenia. Potential benefits of these agents include a more favourable profile in terms of positive and negative symptoms, less adverse effects and better cognitive functioning than first-generation antipsychotics (FGAs). As a consequence, SGAs might favourably affect the capacity, seriously impaired in schizophrenia, of finding and keeping paid employment. To date, only 13 published studies have investigated the effect of SGA agents on employment and work productivity. Clozapine was studied in eight studies, while both olanzapine and risperidone w...Continue Reading

References

Jan 1, 1992·Social Psychiatry and Psychiatric Epidemiology·R G McCreadie
Jan 1, 1992·The Psychiatric Quarterly·J Jaeger, E Douglas
Jan 1, 1991·Schizophrenia Bulletin·T G McGuire
Mar 1, 1987·The British Journal of Psychiatry : the Journal of Mental Science·G FaddenL Kuipers
Jul 1, 1987·The British Journal of Psychiatry : the Journal of Mental Science·A Brown
Jan 1, 1995·Schizophrenia Bulletin·S M Evers, A J Ament
Oct 1, 1994·The American Journal of Psychiatry·J D HegartyG Oepen
Nov 1, 1993·The American Journal of Psychiatry·H Y MeltzerB Snitz
Mar 1, 1996·The American Journal of Psychiatry·M F Green
Apr 1, 1996·Archives of General Psychiatry·M H ChakosJ A Lieberman
Mar 1, 1996·Psychiatric Services : a Journal of the American Psychiatric Association·P Polak, R Warner
Jun 1, 1997·The American Journal of Psychiatry·M F GreenJ Mintz
Aug 1, 1997·The British Journal of Psychiatry : the Journal of Mental Science·K J Aitchison, R W Kerwin
Mar 31, 1998·The British Journal of Psychiatry : the Journal of Mental Science·M Knapp
Aug 12, 1998·The American Journal of Psychiatry·R W BuchananG D Pearlson
Oct 10, 1998·Social Psychiatry and Psychiatric Epidemiology·L MaglianoM Maj
May 8, 1995·Journal of Health Economics·M A KoopmanschapL van Roijen
May 7, 1997·PharmacoEconomics·F RouillonP Auquier
Mar 8, 1997·Journal of Health Economics·M Johannesson, G Karlsson
May 5, 1999·Lancet·S K Schultz, N C Andreasen
Sep 10, 1999·Acta Psychiatrica Scandinavica·B R Rund, N E Borg
Nov 2, 1999·The Australian and New Zealand Journal of Psychiatry·L R DrewK M Griffiths
Nov 5, 1999·The Journal of Clinical Psychiatry·A L MillerS P Shon
Mar 30, 2000·The American Journal of Psychiatry·R M BilderJ A Lieberman
May 2, 2000·The British Journal of Psychiatry : the Journal of Mental Science·J MunroR Kerwin
Sep 19, 2000·International Clinical Psychopharmacology·S H HamiltonA Breier
Nov 7, 2000·PharmacoEconomics·E Lindström, K Bingefors
Dec 1, 2000·BMJ : British Medical Journal·S Kapur, G Remington
Feb 7, 2001·The American Journal of Psychiatry·P D Harvey, R S Keefe
Feb 13, 2001·BMJ : British Medical Journal·R E CrowtherP Huxley
Feb 2, 2002·The American Journal of Psychiatry·David A Lewis

❮ Previous
Next ❯

Citations

Nov 4, 2006·Der Nervenarzt·W W Fleischhacker, W Hummer
Feb 22, 2012·Advances in Therapy·Helen KitchenPat Sacco
Apr 28, 2006·Current Opinion in Psychiatry·Peter F Buckley, Nitin Shendarkar
Dec 13, 2006·Drugs & Aging·Pietro GareriGiovambattista De Sarro
Feb 5, 2008·The Journal of Behavioral Health Services & Research·Sandra G ResnickJeffrey Lieberman
May 9, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Samuel Keith
May 21, 2008·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Bart HeegBen van Hout
Jul 23, 2009·Health Affairs·Robert A Rosenheck, Michael J Sernyak
Feb 19, 2008·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Christian DolderZachariah Deyo
Jan 9, 2020·Psychiatric Services : a Journal of the American Psychiatric Association·Robert E DrakeWilliam D Frey
Sep 16, 2008·European Psychiatry : the Journal of the Association of European Psychiatrists·Alessandro SerrettiDomenico Berardi
Apr 2, 2018·Community Mental Health Journal·Antonia Najas-GarciaTania B Huedo-Medina
Nov 6, 2020·Epidemiology and Psychiatric Sciences·Robert E Drake, Michael A Wallach

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here